Strong Q3 2025 led by Registry Operations and resilient, diversified, Services segment; diluted EPS $0.45Company currently on ...
49m
Exagen (XGN): Revenue Growth Outlook Challenges Bearish Sentiment as Valuation Remains Undemanding
Exagen (XGN) remains unprofitable, but the company has managed to cut its annual losses by 4.7% over the last five years. While forecasts call for continued red ink over the next three years, revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback